J. Carlson

发表

The impact of the Oncotype Dx breast cancer assay in clinical practice: a systematic review and meta-analysis

Josh J. Carlson, Joshua A. Roth, J. Roth, 2013, Breast Cancer Research and Treatment.

Favorable and publicly funded studies are more likely to be published: a systematic review and meta-analysis.

S. Sullivan, J. Carlson, E. Devine, 2017, Journal of clinical epidemiology.

Indirect costs and workplace productivity loss associated with non-Hodgkin lymphoma

J. Carlson, R. Hansen, A. Valderrama, 2016, Leukemia & lymphoma.

Participant Attitudes Toward an Intensive Trial of Multiple Biopsies, Multidimensional Molecular Analysis, and Reporting of Results in Metastatic Triple-Negative Breast Cancer

G. Lyman, C. A. Blau, D. Veenstra, 2017, JCO precision oncology.

Performance-Based Risk-Sharing Arrangements: An Updated International Review

L. Garrison, J. Carlson, Shuxian Chen, 2017, PharmacoEconomics.

Assessing Payers' Preferences for Real-World Evidence in the United States: A Discrete Choice Experiment.

D. Veenstra, J. Carlson, B. Devine, 2021, Value in health : the journal of the International Society for Pharmacoeconomics and Outcomes Research.

How can clinical researchers quantify the value of their proposed comparative research?

J. Probstfield, D. Veenstra, A. Basu, 2019, American heart journal.

Paying for Cures: How Can We Afford It? Managed Care Pharmacy Stakeholder Perceptions of Policy Options to Address Affordability of Prescription Drugs.

L. Garrison, A. Basu, J. Carlson, 2017, Journal of managed care & specialty pharmacy.

THE PROGNOSTIC ROLE OF ERCC1 IN ADVANCED NON-SMALL CELL LUNG CANCER: A SYSTEMATIC REVIEW & META-ANALYSIS

J. Roth, J. Carlson, 2011 .

Prognostic role of ERCC1 in advanced non-small-cell lung cancer: a systematic review and meta-analysis.

J. Roth, J. Carlson, 2011, Clinical lung cancer.

Erlotinib in non-small-cell lung cancer: a review of the clinical and economic evidence

J. Carlson, 2009, Expert review of pharmacoeconomics & outcomes research.

Predicting Low Accrual in the National Cancer Institute's Cooperative Group Clinical Trials.

S. Ramsey, D. Veenstra, A. Basu, 2016, Journal of the National Cancer Institute.

Using Performance-Based Risk-Sharing Arrangements to Address Uncertainty in Indication-Based Pricing.

Meng Li, J. Carlson, K. Yeung, 2017, Journal of managed care & specialty pharmacy.

A Review of Public Policy Issues in Promoting the Development and Commercialization of Pharmacogenomic Applications: Challenges and Implications

Patricia C. Kuszler, L. Garrison, D. Veenstra, 2008, Drug metabolism reviews.

Provider preferences for resolving uncertainty and avoiding harms in precision medicine: a discrete choice experiment.

D. Veenstra, A. Basu, D. Regier, 2020, Personalized medicine.

Are there different evidence thresholds for genomic vs. clinical precision medicine? A VOI-based framework applied to antiplatelet drug therapy

D. Veenstra, A. Basu, J. Carlson, 2019 .

Economic consequences of sequencing biologics in rheumatoid arthritis: a systematic review

R. Alfonso-Cristancho, S. Sullivan, J. Carlson, 2013, Journal of medical economics.

Budget impact analysis of the DiviTum TKa assay in postmenopausal women with hormone receptor positive metastatic breast cancer

S. Ramsey, R. Dann, J. Carlson, 2021, Journal of medical economics.

Getting our priorities straight: a novel framework for stakeholder-informed prioritization of cancer genomics research

S. Ramsey, D. Veenstra, L. Esmail, 2012, Genetics in Medicine.

The potential clinical and economic outcomes of pharmacogenomic approaches to EGFR-tyrosine kinase inhibitor therapy in non-small-cell lung cancer.

L. Garrison, S. Ramsey, D. Veenstra, 2009, Value in health : the journal of the International Society for Pharmacoeconomics and Outcomes Research.

Cost-effectiveness of erlotinib vs. docetaxel or pemetrexed in the treatment of refractory non-small cell lung cancer (NSCLC)

D. Lubeck, S. Ramsey, N. Oestreicher, 2007 .

JAK inhibitors and monoclonal antibodies for the treatment of atopic dermatitis: effectiveness and value

S. Atlas, D. Rind, J. Carlson, 2022, Journal of managed care & specialty pharmacy.

Economic Evaluation of Dupilumab for Moderate-to-Severe Atopic Dermatitis: A Cost-Utility Analysis.

D. Rind, J. Carlson, Varun Kumar, 2018, Journal of drugs in dermatology : JDD.

Defining and Managing High-Priced Cures: Healthcare Payers' Opinions.

L. Garrison, J. Carlson, K. Suh, 2019, Value in health : the journal of the International Society for Pharmacoeconomics and Outcomes Research.

Integrating value of research into NCI Clinical Trials Cooperative Group research review and prioritization: A pilot study

David D. Kim, S. Ramsey, D. Veenstra, 2018, Cancer medicine.

Development and Evaluation of an Approach to Using Value of Information Analyses for Real-Time Prioritization Decisions Within SWOG, a Large Cancer Clinical Trials Cooperative Group

S. Ramsey, D. Veenstra, A. Basu, 2016, Medical decision making : an international journal of the Society for Medical Decision Making.

Cost-Effectiveness of Gemcitabine + Cisplatin vs. Gemcitabine Monotherapy in Advanced Biliary Tract Cancer

J. Roth, J. Carlson, 2012, Journal of Gastrointestinal Cancer.

Cost-Effectiveness Uncertainty Analysis Methods

Jonathan D. Campbell, A. Briggs, J. Carlson, 2015, Medical decision making : an international journal of the Society for Medical Decision Making.

Does Clinical Evidence of Heterogeneity Impact Treatment Selection? A Case Study of Abiraterone for Metastatic Prostate Cancer.

L. Garrison, A. Basu, J. Carlson, 2022, Journal of the National Comprehensive Cancer Network : JNCCN.

Can we predict trial failure among older adult-specific clinical trials using trial-level factors?

D. Veenstra, A. Basu, J. Carlson, 2022, Journal of geriatric oncology.

Cost-effectiveness of Drugs to Treat Relapsed/Refractory Multiple Myeloma in the United States

J. Carlson, S. Pearson, R. Chapman, 2018, Journal of managed care & specialty pharmacy.

Paying for personalized care: Cancer biomarkers and comparative effectiveness

L. Garrison, S. Ramsey, D. Veenstra, 2012, Molecular oncology.

Influence of Modeling Choices on Value of Information Analysis: An Empirical Analysis from a Real-World Experiment

Josh J. Carlson, Scott D. Ramsey, Anirban Basu, 2019, PharmacoEconomics.

Demand for Precision Medicine: A Discrete-Choice Experiment and External Validation Study

D. Veenstra, A. Basu, D. Regier, 2019, PharmacoEconomics.

Comparative effectiveness of larotrectinib and entrectinib for TRK fusion cancer.

A. Italiano, S. Sullivan, S. Kummar, 2022, The American journal of managed care.

Cost-Effectiveness of a Biopsy-Based 8-Protein Prostate Cancer Prognostic Assay to Optimize Treatment Decision Making in Gleason 3 + 3 and 3 + 4 Early Stage Prostate Cancer.

S. Ramsey, J. Roth, J. Carlson, 2015, The oncologist.

Cost Effectiveness of Alectinib vs. Crizotinib in First-Line Anaplastic Lymphoma Kinase-Positive Advanced Non-Small-Cell Lung Cancer

Josh J Carlson, J. Carlson, K. Suh, 2018, PharmacoEconomics.

Stakeholder assessment of the evidence for cancer genomic tests: insights from three case studies

M. Khoury, K. Goddard, S. Schully, 2012, Genetics in Medicine.

Comparative effectiveness of larotrectinib versus entrectinib for the treatment of metastatic NTRK gene fusion cancers.

S. Sullivan, J. Carlson, K. Suh, 2022, Journal of comparative effectiveness research.

Cost Effectiveness of Pharmacogenomics

Josh J. Carlson, Rahber Thariani, D. Veenstra, 2012, PharmacoEconomics.

Epidermal growth factor receptor genomic variation in NSCLC patients receiving tyrosine kinase inhibitor therapy: a systematic review and meta-analysis

L. Garrison, S. Ramsey, D. Veenstra, 2009, Journal of Cancer Research and Clinical Oncology.

Proof or principle? On economic modeling to guide genomic testing in metastatic colorectal cancer.

S. Ramsey, J. Carlson, 2012, Journal of the National Cancer Institute.

Economic analyses of human genetics services: A systematic review

S. Ramsey, D. Veenstra, J. Carlson, 2005, Genetics in Medicine.

Clinical and economic review of erlotinib in non-small-cell lung cancer

J. Carlson, K. Yeung, 2012, Expert review of pharmacoeconomics & outcomes research.

Alternative Approaches to Quality-Adjusted Life-Year Estimation Within Standard Cost-Effectiveness Models: Literature Review, Feasibility Assessment, and Impact Evaluation.

Josh J. Carlson, Eunice Kim, Elizabeth Brouwer, 2020, Value in health : the journal of the International Society for Pharmacoeconomics and Outcomes Research.

Toward evidence-based assessment for coverage and reimbursement of laboratory-based diagnostic and genetic tests.

Scott D Ramsey, Louis P Garrison, Sean D Sullivan, 2006, The American journal of managed care.

A Framework for Prioritizing Research Investments in Precision Medicine

D. Veenstra, A. Basu, J. Carlson, 2016, Medical decision making : an international journal of the Society for Medical Decision Making.

Linking payment to health outcomes: a taxonomy and examination of performance-based reimbursement schemes between healthcare payers and manufacturers.

Louis P Garrison, Sean D Sullivan, David L Veenstra, 2010, Health policy.

The Cost-Effectiveness of Financial Incentives for Viral Suppression: HPTN 065 Study.

Blythe J. S. Adamson, L. Garrison, W. El-Sadr, 2019, Value in health : the journal of the International Society for Pharmacoeconomics and Outcomes Research.

Are There Different Evidence Thresholds for Genomic Versus Clinical Precision Medicine? A Value of Information-Based Framework Applied to Antiplatelet Drug Therapy.

D. Veenstra, A. Basu, J. Carlson, 2019, Value in health : the journal of the International Society for Pharmacoeconomics and Outcomes Research.

Comparative Effectiveness of Biomarkers to Target Cancer Treatment

Ruth Etzioni, Josh J Carlson, Ruth Etzioni, 2016, Medical decision making : an international journal of the Society for Medical Decision Making.

Current Status and Trends in Performance-Based Risk-Sharing Arrangements Between Healthcare Payers and Medical Product Manufacturers

L. Garrison, S. Sullivan, J. Carlson, 2014, Applied Health Economics and Health Policy.

Estimating the cost-effectiveness of onabotulinumtoxinA for neurogenic detrusor overactivity in the United States.

R. Dmochowski, S. Sullivan, D. Globe, 2013, Clinical therapeutics.

The Potential Cost-Effectiveness of Pre-Exposure Prophylaxis Combined with HIV Vaccines in the United States

Blythe J. S. Adamson, J. Kublin, L. Garrison, 2017, Vaccines.

Competing biomedical HIV prevention strategies: potential cost‐effectiveness of HIV vaccines and PrEP in Seattle, WA

Blythe J. S. Adamson, J. Kublin, L. Garrison, 2019, Journal of the International AIDS Society.

Cost-savings for biosimilars in the United States: a theoretical framework and budget impact case study application using filgrastim

S. Ramsey, J. Carlson, S. Grewal, 2018, Expert review of pharmacoeconomics & outcomes research.

Multigene assays and molecular markers in breast cancer: systematic review of health economic analyses

R. Rouzier, E. Chéreau, J. Carlson, 2013, Breast Cancer Research and Treatment.

Exploring Medication Adherence with P2Y12 Inhibitors Using Conditional and Unconditional Quantile Regression Approaches

A. Basu, J. Carlson, K. Branch, 2020, American Journal of Cardiovascular Drugs.

The cost-effectiveness of alectinib in anaplastic lymphoma kinase-positive (ALK+) advanced NSCLC previously treated with crizotinib

J. Carlson, W. Canestaro, W. Wong, 2017, Journal of medical economics.

Online tools to synthesize real-world evidence of comparative effectiveness research to enhance formulary decision making

D. Veenstra, A. Basu, J. Carlson, 2021, Journal of managed care & specialty pharmacy.

Economic evaluation of tocilizumab monotherapy compared to adalimumab monotherapy in the treatment of severe active rheumatoid arthritis.

S. Sullivan, J. Carlson, S. Ogale, 2015, Value in health : the journal of the International Society for Pharmacoeconomics and Outcomes Research.

Quantifying the value of older adult-specific clinical trials: Post-lumpectomy irradiation among older adults with early-stage breast cancer.

D. Veenstra, A. Basu, J. Carlson, 2023, Journal of geriatric oncology.

PRM47 Cost-Effectiveness Uncertainty Analysis Methods: A Comparison of One-Way Sensitivity, Analysis of Covariance, and Expected Value of Partial Perfect Information

Jonathan D. Campbell, A. Briggs, E. Spackman, 2011 .

An evaluation of the potential cost‐effectiveness of non‐invasive testing strategies in the diagnosis of significant liver fibrosis

S. Ramsey, S. Sullivan, K. Kowdley, 2009, Journal of gastroenterology and hepatology.

Cost-Effectiveness of Cannabidiol Adjunct Therapy versus Usual Care for the Treatment of Seizures in Lennox-Gastaut Syndrome

D. Veenstra, J. Carlson, E. Neuberger, 2020, PharmacoEconomics.

Author's Reply to Letter-to-the-Editor: Cost Utility of Voretigene Neparvovec for Biallelic RPE65-Mediated Inherited Retinal Disease

D. Rind, J. Carlson, R. Chapman, 2019 .

Cost-effectiveness of a 14-gene risk score assay to target adjuvant chemotherapy in early stage non-squamous non-small cell lung cancer.

S. Ramsey, J. Roth, J. Carlson, 2014, The oncologist.

Cost‐effectiveness analysis of low‐dose direct oral anticoagulant (DOAC) for the prevention of cancer‐associated thrombosis in the United States

A. Khorana, G. Lyman, J. Carlson, 2020, Cancer.

Exploring the Cost Effectiveness of Shared Decision Making for Choosing between Disease-Modifying Drugs for Relapsing-Remitting Multiple Sclerosis in the Netherlands: A State Transition Model

M. Hiligsmann, N. Bansback, P. Jongen, 2020, Medical decision making : an international journal of the Society for Medical Decision Making.

Targeted erlotinib for first-line treatment of advanced non-small cell lung cancer: a budget impact analysis

D. Veenstra, J. Carlson, Hans-Peter Goertz, 2014, Journal of medical economics.

Budget impact of erlotinib for maintenance therapy in advanced non-small cell lung cancer

D. Veenstra, J. Carlson, C. Reyes, 2011, Journal of medical economics.

The potential long-term comparative effectiveness of larotrectinib versus entrectinib for treatment of metastatic TRK fusion colorectal cancer.

S. Sullivan, J. Carlson, K. Suh, 2022, Journal of Clinical Oncology.

Disease-Modifying Therapies for Relapsing–Remitting and Primary Progressive Multiple Sclerosis: A Cost-Utility Analysis

J. Tice, J. Carlson, R. Chapman, 2018, CNS Drugs.

Pharmacoeconomic Evaluations in the Treatment of Non-Small Cell Lung Cancer

S. Ramsey, D. Veenstra, J. Carlson, 2012, Drugs.

Achieving Appropriate Model Transparency: Challenges and Potential Solutions for Making Value-Based Decisions in the United States

David Veenstra, Josh J. Carlson, Anirban Basu, 2019, PharmacoEconomics.

Value-of-Information Analysis within a Stakeholder-Driven Research Prioritization Process in a US Setting: An Application in Cancer Genomics

Rahber Thariani, Scott D Ramsey, David L Veenstra, 2013, Medical decision making : an international journal of the Society for Medical Decision Making.

Private sector risk-sharing agreements in the United States: trends, barriers, and prospects.

Louis P Garrison, Sean D Sullivan, Kimberly Westrich, 2015, The American journal of managed care.

Comparative clinical and economic outcomes of treatments for refractory non-small cell lung cancer (NSCLC).

Scott D Ramsey, David L Veenstra, Josh J Carlson, 2008, Lung cancer.

Understanding the Economic Value of Molecular Diagnostic Tests: Case Studies and Lessons Learned

L. Garrison, D. Veenstra, J. Carlson, 2013, Journal of personalized medicine.

Cost Utility of Voretigene Neparvovec for Biallelic RPE65-Mediated Inherited Retinal Disease.

D. Rind, J. Carlson, R. Chapman, 2019, Value in health : the journal of the International Society for Pharmacoeconomics and Outcomes Research.

Paying for Outcomes: Innovative Coverage and Reimbursement Schemes for Pharmaceuticals

L. Garrison, S. Sullivan, J. Carlson, 2009, Journal of managed care pharmacy : JMCP.

The Effectiveness and Value of Lanadelumab and C1 Esterase Inhibitors for Prophylaxis of Hereditary Angioedema Attacks.

Grace A Lin, J. Carlson, S. Pearson, 2019, Journal of managed care & specialty pharmacy.

Best Available Therapy Versus Autologous Hematopoietic Stem Cell Transplantation for Multiple Sclerosis

Jeffrey A. Cohen, Deborah M. Miller, D. Arnold, 2020 .

Comparative effectiveness research in the United States: a progress report

S. Sullivan, J. Carlson, R. Hansen, 2013, Journal of medical economics.

Key learnings from Institute for Clinical and Economic Review’s real-world evidence reassessment pilot

A. Patrick, J. Carlson, Yilin Chen, 2022, International Journal of Technology Assessment in Health Care.

HTA’d in the USA: A Comparison of ICER in the United States with NICE in England and Wales

M. Drummond, P. Thokala, J. Carlson, 2020, Journal of managed care & specialty pharmacy.

Health Years in Total: A New Health Objective Function for Cost-Effectiveness Analysis.

David Veenstra, Anirban Basu, D. Veenstra, 2020, Value in health : the journal of the International Society for Pharmacoeconomics and Outcomes Research.

How Much Does the US Public Value Equity in Health? A Systematic Review.

J. Carlson, S. Khor, Z. Elsisi, 2022, Value in health : the journal of the International Society for Pharmacoeconomics and Outcomes Research.

Use of real-world evidence in economic assessments of pharmaceuticals in the United States

D. Veenstra, J. Carlson, B. Devine, 2021, Journal of managed care & specialty pharmacy.

The use of real-world evidence in ICER’s scoping process and clinical evidence assessments

D. Veenstra, J. Carlson, B. Devine, 2020, Journal of Managed Care & Specialty Pharmacy.

KEY LEARNINGS FROM ICER'S REAL WORLD EVIDENCE REASSESSMENT PILOT.

A. Patrick, J. Carlson, L. Bloudek, 2022, International journal of technology assessment in health care.

Using comprehensive disease modeling to assess the burden of substandard and falsified oxytocin in Kenya

J. Carlson, E. Vodicka, S. Zaraa, 2023, medRxiv.

PHP146 Current Status and Trends in Performance-Based Schemes Between Health Care Payers and Manufacturers

L. Garrison, S. Sullivan, J. Carlson, 2011 .

Ready for genomic medicine? Perspectives of health care decision makers.

W. Everett, J. Carlson, P. Billings, 2005, Archives of internal medicine.

Optimal treatment sequence for targeted immune modulators for the treatment of moderate to severe ulcerative colitis

J. Carlson, D. Ollendorf, L. Bloudek, 2021, Journal of managed care & specialty pharmacy.

The effectiveness and value of AMX0035 and oral edaravone for amyotrophic lateral sclerosis: A summary from the Institute for Clinical and Economic Review’s Midwest Comparative Effectiveness Public Advisory Council

D. Rind, J. Carlson, A. Makam, 2023, Journal of managed care & specialty pharmacy.

Prioritization in Comparative Effectiveness Research: The CANCERGEN Experience

Rahber Thariani, Laura Esmail, Scott Ramsey, 2012, Medical care.

Use of Epidermal Growth Factor Receptor Mutation Analysis in Patients with Advanced Non-Small-Cell Lung Cancer to Determine Erlotinib Use as First-Line Therapy

S. Schully, S. Ramsey, A. Freedman, 2011, PLoS currents.

Original article Budget impact of erlotinib for maintenance therapy in advanced non-small cell lung cancer

D. Veenstra, J. Carlson, C. Reyes, 2011 .

Linking payment to health outcomes: a taxonomy and examination of performance-based reimbursement schemes between healthcare payers and manufacturers.

L. Garrison, S. Sullivan, D. Veenstra, 2010, Health policy.

Incorporating Dynamic Pricing in Cost-Effectiveness Analysis: Are Known Unknowns Valuable?

J. Carlson, R. McQueen, J. Levy, 2023, PharmacoEconomics (Auckland).

The cost of relapse in Hodgkin lymphoma.

S. Ramsey, J. Carlson, R. Hansen, 2014 .

Paying for Outcomes: Innovative Coverage and Reimbursement Schemes for Pharmaceuticals

L. Garrison, S. Sullivan, J. Carlson, 2009, Journal of managed care pharmacy : JMCP.

Cost-savings for biosimilars in the United States: a theoretical framework and budget impact case study application using filgrastim

S. Ramsey, J. Carlson, S. Grewal, 2018, Expert review of pharmacoeconomics & outcomes research.

Economic Burden of Metastatic Ovarian Cancer in a Commercially Insured Population: A Retrospective Cohort Analysis

J. Carlson, R. Hansen, L. Chin, 2020, Journal of managed care & specialty pharmacy.

JAK inhibitors and monoclonal antibodies for the treatment of atopic dermatitis: effectiveness and value

S. Atlas, D. Rind, J. Carlson, 2022, Journal of managed care & specialty pharmacy.

Performance-based risk-sharing arrangements for devices and diagnostics in the United States: a systematic review

J. Carlson, Yilin Chen, 2022, Journal of managed care & specialty pharmacy.